The European Society for Clinical Oncology (ESMO) Congress 2024 was held in September of 2024. Mary Crowley Cancer Research was proud to be one of the thousands in attendance of the annual conference held this year in Barcelona, Spain.
At ESMO Congress 2024, Dr. Minal Barve, Chief Medical Officer for Mary Crowley Cancer Research, had the opportunity to meet with representatives from 18 key companies in the industry.
Beyond that, Mary Crowley Cancer Research contributed to a total of eight abstracts, five of which were selected for poster presentation and three for oral presentation. View them at the links below:
Trial # 20-08: https://marycrowley.org/2024/09/24/dazostinag-tak-676-alone-and-in-combination-with-pembrolizumab-in-patients-with-advanced-metastatic-solid-tumors-data-from-phase-1-dose-escalation/
Trial # 21-25: https://marycrowley.org/2024/09/24/updated-data-from-beamionlung-1-a-phase-ia-b-trial-of-the-her2-specific-tyrosine-kinase-inhibitor-zongertinibbi-1810631-in-patients-with-her2-mutation-positive-nsclc/
Trial # 21-41: https://marycrowley.org/2024/09/24/phase-1-2-trial-of-asp1570-a-novel-diacylglycerol-kinase-%ce%b6-inhibitor-in-patients-with-advanced-solid-tumors/
Trial # 22-02: https://marycrowley.org/2024/09/24/results-from-the-first-in-human-study-of-atr-inhibitor-imp9064-monotherapy-dose-escalation-in-patients-with-advanced-solid-tumors/
Trial # 22-33: https://marycrowley.org/2024/09/24/a-phase-1-2-study-of-rinatabart-sesutecan-rina-s-in-patients-with-advanced-ovarian-or-endometrial-cancer/
Trial # 22-39: https://marycrowley.org/2024/09/24/trial-in-progress-a-phase-1-2a-trial-of-aurora-a-inhibitor-jab-2485-in-adult-patients-with-advanced-solid-tumors/
Trial # 22-42: https://marycrowley.org/2024/09/24/first-in-human-phase-i-dose-escalation-study-of-alg-apv-527-a-5t4-tumor-antigen-conditional-4-1bb-bispecific-antibody-in-patients-with-advanced-solid-tumors-demonstrates-positive-safety-signals-of/
Trial # 23-06: https://marycrowley.org/2024/09/24/first-in-human-results-of-stx-478-a-mutant-selective-pi3k%ce%b1-inhibitor-in-advanced-solid-tumor-patients/
Dr. Barve stated, “It was indeed an honor to represent Mary Crowley Cancer Research, and I would like to thank all of our staff who make our organization so successful, internationally recognized, and respected.”
Mary Crowley Cancer Research would also like to thank all their patients and other supporters, without them MCCR would not be able to attend such prestigious and critical conferences.
